These BMICs also displayed varying expression levels of the cancer stem cell markers CD44 (15, 16) and CD133 (17, 18) (SI Appendix, Fig. S1 D and E) indicative of interpatient heterogeneity and importantly the need for more defined BMIC markers. Here, CD44 is linked to cancer.